About Intellia Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.intelliatx.com/
Frequently Asked Questions
What is the 52-week range for NTLA?
The 52-week high is $28.25 and the 52-week low is $7.95.
What is the P/E ratio for NTLA?
The P/E ratio data is currently unavailable.
What is the dividend yield for NTLA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -57.79%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -672.16%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.55.
Analyst Recommendation Trends
Wall Street analyst consensus for NTLA over the last few months:
Latest NTLA News
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Could This Cathie Wood Stock Soar in 2027?
This biotech has grabbed plenty of headlines recently.
Intellia Therapeutics Bears Growl Again, This Time About Claude AI -- Yawn!
Intellia update: Claude AI flags a gene-editing setup but canât replicate it. Lonvo-z targets a 2027 launch; Nex-z enrollment rebounds. Click for more on NTLA stock.
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
Anthropic AI Discovery Gene-Editing Stocks Falling
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy
Intellia Therapeutics (NasdaqGM:NTLA) said the FDA accepted its Biologics License Application for lonvo-z for hereditary angioedema. The agency granted Priority Review status, positioning lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. The FDA does not plan to convene an advisory committee, with review supported by positive Phase 3 data and multiple global designations. The FDA's Priority Review of lonvo-z for hereditary angioedema is a key regulatory event to weigh...
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event. Chief Executive Officer
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDTCompany ParticipantsJohn Leonard -...
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
The FDA accepted Intellia’s Biologics License Application for lonvoguran Ziclumeran for Hereditary Angioedema.
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
Intellia Therapeutics (NASDAQ:NTLA) shares rose 8% on Tuesday after the U. S.
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biol
Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
Intellia Therapeutics (NTLA) stock is in focus after the company arranged a $400 million non dilutive senior secured term loan facility with OrbiMed to support lonvoguran ziclumeran, or lonvo z, development and launch plans. The financing news comes after a mixed period for Intellia Therapeutics. The share price is US$12.74, with a 30-day share price return of 16.13%, but the 3-year total shareholder return has declined 66.36% and the 5-year total shareholder return has declined 92.07%. Scan...
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
Intellia Therapeutics recently entered into a US$400 million non-dilutive senior secured term loan facility with OrbiMed, including a US$75 million initial draw and milestone-based tranches primarily linked to lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, with full details to follow in an SEC Form 8-K filing. This financing structure, which ties most of the available capital to lonvo-z development milestones, highlights how central that program has become to Intellia’s funding...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an agg
Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection pointsCAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a $400 million non-dilutive senior secured term loan facility with OrbiMed,
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET. A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’
Intellia Therapeutics Enters Into $400M Non-Dilutive Senior Secured Term Loan Facility With OrbiMed
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a
Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting?
Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and ARKW are betting on next.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-21 | LEONARD JOHN M | -2,785 | $13 | $36,205 |
| 2026-08-20 | LEONARD JOHN M | -19,890 | $12.6 | $250,614 |
| 2026-07-22 | Dulac Edward J III | -8,111 | $11.25 | $91,249 |
| 2026-07-02 | Dulac Edward J III | -4,677 | $18 | $84,186 |
| 2026-07-01 | Dube Michael P | -2,641 | $16.78 | $44,316 |
| 2026-06-09 | GOODMAN JESSE | +13,300 | - | - |
| 2026-06-09 | GOODMAN JESSE | +9,200 | - | - |
| 2026-06-09 | Keresty Georgia | +13,300 | - | - |
| 2026-06-09 | Keresty Georgia | +9,200 | - | - |
| 2026-06-09 | Bhanji Muna | +13,300 | - | - |
| 2026-06-09 | Bhanji Muna | +9,200 | - | - |
| 2026-06-09 | CHASE WILLIAM J | +13,300 | - | - |
| 2026-06-09 | CHASE WILLIAM J | +9,200 | - | - |
| 2026-06-09 | Goff Brian | +13,300 | - | - |
| 2026-06-09 | Goff Brian | +9,200 | - | - |
| 2026-06-09 | Verwiel Frank | +13,300 | - | - |
| 2026-06-09 | Verwiel Frank | +9,200 | - | - |
| 2026-06-09 | Cohen Fred E | +13,300 | - | - |
| 2026-06-09 | Cohen Fred E | +9,200 | - | - |
| 2026-03-02 | BASTA JAMES | -1,211 | $13.78 | $16,688 |
| 2026-03-02 | Clark Eliana | -607 | $13.78 | $8,364 |
| 2026-03-01 | BASTA JAMES | +65,829 | - | - |
| 2026-03-01 | BASTA JAMES | +46,080 | - | - |
| 2026-03-01 | Clark Eliana | +10,505 | - | - |
| 2026-03-01 | Clark Eliana | +7,353 | - | - |
| 2026-03-01 | Dube Michael P | +17,250 | - | - |
| 2026-03-01 | LEONARD JOHN M | +225,400 | - | - |
| 2026-03-01 | LEONARD JOHN M | +156,400 | - | - |
| 2026-03-01 | Lebwohl David | +14,204 | - | - |
| 2026-03-01 | Lebwohl David | +9,943 | - | - |
| 2026-03-01 | Dulac Edward J III | +87,543 | - | - |
| 2026-03-01 | Dulac Edward J III | +61,280 | - | - |
| 2026-03-01 | Schultes Birgit C | +56,000 | - | - |
| 2026-03-01 | Schultes Birgit C | +39,200 | - | - |
| 2026-01-05 | Schultes Birgit C | -8,508 | $9.21 | $78,359 |
| 2026-01-05 | BASTA JAMES | -10,397 | $9.21 | $95,756 |
| 2026-01-05 | Lebwohl David | -11,903 | $9.21 | $109,627 |
| 2026-01-05 | Clark Eliana | -9,515 | $9.21 | $87,633 |
| 2026-01-05 | Dulac Edward J III | -6,379 | $9.21 | $58,751 |
| 2026-01-05 | Dube Michael P | -2,989 | $9.21 | $27,529 |
| 2026-01-05 | LEONARD JOHN M | -34,146 | $9.21 | $314,485 |
| 2026-01-05 | Cohen Fred E | +150,000 | $9.35 | $1,402,500 |
| 2025-12-12 | LEONARD JOHN M | -8,557 | - | - |
| 2025-12-12 | LEONARD JOHN M | +8,557 | $6.83 | $58,444 |
| 2025-12-11 | LEONARD JOHN M | -49,959 | - | - |
| 2025-12-11 | LEONARD JOHN M | -5,355 | $9.59 | $51,354 |
| 2025-12-11 | LEONARD JOHN M | -32,832 | $9.47 | $310,919 |
| 2025-12-11 | LEONARD JOHN M | -49,959 | $9.49 | $474,111 |
| 2025-12-11 | LEONARD JOHN M | +49,959 | $6.83 | $341,220 |